Filing summary
Identity and period: The supplied filing is IsoRay, Inc.’s Form 10-K for the fiscal year ended June 30, 2016—not a 2015 Q4 report. The filing does not identify the registrant as Perspective Therapeutics, Inc.; confirm the intended company and filing before relying on this summary.
Business context and financial results
IsoRay develops, manufactures, and sells Cesium-131 (Cs-131) brachytherapy products for cancer treatment. Prostate treatment remained its core business; the company was also developing use in brain, gynecological, lung, and head-and-neck cancers. The filing reports one operating segment.
| Metric | FY2016 | FY2015 |
|---|---|---|
| Net product sales | $4.77 million | $4.61 million |
| Gross profit / margin | $129,154 / 2.7% | $167,393 / 3.6% |
| Operating loss | $5.08 million | $4.34 million |
| Net loss | $4.71 million | $3.68 million |
| Basic and diluted loss per share | $0.09 | $0.07 |
| Cash used in operations | $3.88 million | $3.52 million |
Sales grew 4%, but cost of sales was 97% of revenue, leaving a narrow gross margin. Prostate brachytherapy sales rose 3% to $4.09 million; other brachytherapy sales increased 31% to $658,305, while GliaSite RTS sales fell 85% to $17,174. Prostate products represented about 86% of sales.
Liquidity, cash flow, and obligations
- At June 30, 2016, cash and cash equivalents were $10.14 million; certificates of deposit totaled $5.22 million, including current and non-current amounts. The filing separately reports $181,420 of restricted cash.
- Working capital was $12.54 million and the current ratio was 12.47, down from 14.95 a year earlier.
- Operating cash outflow increased to $3.88 million. Investing cash inflow of $8.76 million largely reflected certificate-of-deposit maturities and purchases; financing provided $39,308.
- Total liabilities were $1.70 million, including $580,480 of asset-retirement obligation and a $27,000 warrant derivative liability. The balance sheet shows no conventional borrowings; operating lease commitments totaled $800,371.
- Management said cash and certificates of deposit, together with projected sales, were expected to support operations at then-current expense and revenue levels for four years.
Changes, outlook, and material items
- Operating loss widened 17% and net loss widened approximately 28% year over year, despite sales growth. General and administrative expense rose substantially, primarily due to securities-litigation costs, leadership changes, staffing, and GliaSite discontinuation costs.
- A non-recurring $456,284 gain from revising the asset-retirement estimate reduced FY2016 expenses; it is not expected to recur absent material changes in assumptions.
- The company discontinued GliaSite RTS in March 2016, citing weak sales, foreign-exchange pressure in Europe, and increased use of Cs-131 seed formats for brain treatment.
- For FY2017, management targeted 20% revenue growth and planned increased sales and marketing investment. It estimated cash-flow break-even in three to five years if targeted growth were achieved and sustained; neither outcome was assured. Planned production-process automation investment was approximately $500,000.
- A new production facility was under design, but construction depended on acceptable financing. The company also faced a development-plan obligation tied to its purchased adjacent property.
Principal risks and contingencies
- Product and market concentration: Revenue depended on one product, with about 86% from prostate treatment. Five customers accounted for approximately 53% of sales, including about 24% from one customer group.
- Isotope supply: Approximately 83% of FY2016 Cs-131 came from a Russian supplier under an agreement ending March 31, 2017. Domestic supply expansion was not assured; the company cited potential geopolitical, payment, and supplier-interruption risks.
- Commercial and reimbursement risks: Prostate brachytherapy faced declining market share, competing treatments, screening and active-surveillance trends, and uncertainty over future reimbursement. Inpatient non-prostate procedures may be less attractive to hospitals because seeds are included in bundled DRG payments.
- Litigation: A securities class action related to a 2015 press release remained pending. The court denied the company’s motion to dismiss without deciding the merits. Management said loss was not considered probable or reasonably estimable; trial was scheduled for June 2018.
- Other risks: Continued losses, possible future dilutive financing, regulatory compliance, product liability, supply-chain concentration, and execution of sales growth and facility plans.
- The independent auditor issued an unqualified opinion on the financial statements and internal controls; management also reported effective disclosure controls and internal control over financial reporting.
Key facts for investors to verify
- Confirm the intended issuer and period: the supplied filing is IsoRay FY2016, while the request identifies Perspective Therapeutics and 2015 Q4.
- Review audited statements and cash, certificate-of-deposit, and burn-rate disclosures; the filing’s narrative says $15.36 million of cash and CDs, while the balance sheet presents them in separate current and non-current line items.
- Check the Russian isotope contract’s renewal or replacement and actual MURR supply capacity and terms.
- Track quarterly revenue, gross margin, customer concentration, and progress toward the FY2017 20% growth target.
- Review the securities-litigation developments, financing needs, and financing status and milestones for the proposed facility.
- Reconcile minor filing-text inconsistencies, including FY2016 sales figures shown as both $4,769,276 and $4,769,216 in different sections.